Effectiveness and Safety of Colloidal Dispersion of Amphotericin B for Treating Mucormycosis: Insights from Real-World Data

1

Mucormycosis is a rare but fatal fungal infection, particularly affecting immunocompromised patients, with a global incidence of 2.7/100,000.
2

Amphotericin B remains the primary treatment for mucormycosis, with delayed treatment significantly increasing mortality rates.
3

ABCD, a colloidal dispersion of Amphotericin B, was authorized in China to improve accessibility and is recommended at 3-4 mg/kg/day.
4

A study of 38 patients treated with ABCD assessed efficacy and safety, documenting survival rates and adverse drug reactions.
5

The study's findings contribute to understanding the real-world effectiveness of ABCD in treating mucormycosis and its safety profile.

Bmc Infectious Diseases

by Ying-Kui Jiang, Wen-Jia Qiu, Yun Cao, Jun-Tian Huang, Rong-Sheng Zhu, Ling-Hong Zhou, Hua-Zhen Zhao, Jie Tong, Zhong-Qing Chen, Li-Ping Zhu
February 10, 2026

1